The gut-eye axis in inflammatory bowel disease: shared immune mechanisms and targeted therapies
- 1Department of Emergency, Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University
- 2Hainan Eye Hospital and Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University
Abstract
Inflammatory bowel disease (IBD) is recognized not only as a disease confined to the intestinal tract, but also as a systemic immune-mediated disorder. Among its diverse extraintestinal manifestations, ocular complications, which range from self-limiting episcleritis to severe and sight-threatening uveitis and scleritis, represent a critical clinical challenge that profoundly impacts patient quality of life. This review synthesizes the epidemiological landscape and clinical spectrum of ocular manifestations in IBD, framing their pathogenesis through the emerging concept of the gut-eye axis. We critically examine the shared mechanistic pathways driving this bidirectional relationship, including the systemic dissemination of circulating inflammatory cytokines, aberrant lymphocyte homing, cross-reactive autoantibodies, shared genetic susceptibilities, and microbiota dysbiosis, which collectively compromise the blood-ocular barrier. Furthermore, we outline targeted therapeutic strategies, highlighting that while systemic anti-TNF agents remain the cornerstone for severe and refractory ocular inflammation, gut-selective biologics like vedolizumab necessitate careful application due to the risk of extraintestinal exacerbation. Finally, we underscore the indispensable role of multidisciplinary management and highlight future research trajectories.
Related
- Biologic and small-molecule therapies for inflammatory bowel disease: mechanisms, comparative evidence and the emerging pipeline
- Mechanisms of inflammatory cell activation in periodontitis-induced bone destruction and advances in targeted interventions
- Comparative efficacy and safety of subcutaneous vedolizumab versus other targeted inflammatory bowel therapies in patients with moderate to severe ulcerative colitis: a network meta-analysis update.
- Identification of a shared PAX5-mediated B-cell regulatory axis in inflammatory bowel disease and rheumatoid arthritis
- Targeted therapies in atopic dermatitis: toward endotype-driven precision medicine and disease modification
BibTeX
@article{fu2026guteye,
title = {{The gut-eye axis in inflammatory bowel disease: shared immune mechanisms and targeted therapies}},
author = {Xuewei Fu and Shisi Hu},
journal = {Frontiers in Immunology},
year = {2026},
month = oct,
doi = {10.3389/fimmu.2026.1997593},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1997593/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - The gut-eye axis in inflammatory bowel disease: shared immune mechanisms and targeted therapies
AU - Xuewei Fu
AU - Shisi Hu
PY - 2026
DA - 2026/10/26
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1997593
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1997593/full
AB - Inflammatory bowel disease (IBD) is recognized not only as a disease confined to the intestinal tract, but also as a systemic immune-mediated disorder. Among its diverse extraintestinal manifestations, ocular complications, which range from self-limiting episcleritis to severe and sight-threatening uveitis and scleritis, represent a critical clinical challenge that profoundly impacts patient quality of life. This review synthesizes the epidemiological landscape and clinical spectrum of ocular manifestations in IBD, framing their pathogenesis through the emerging concept of the gut-eye axis. We critically examine the shared mechanistic pathways driving this bidirectional relationship, including the systemic dissemination of circulating inflammatory cytokines, aberrant lymphocyte homing, cross-reactive autoantibodies, shared genetic susceptibilities, and microbiota dysbiosis, which collectively compromise the blood-ocular barrier. Furthermore, we outline targeted therapeutic strategies, highlighting that while systemic anti-TNF agents remain the cornerstone for severe and refractory ocular inflammation, gut-selective biologics like vedolizumab necessitate careful application due to the risk of extraintestinal exacerbation. Finally, we underscore the indispensable role of multidisciplinary management and highlight future research trajectories.
SN - 1664-3224
ER -